Physician profile
Carol A Wolfe
NPI 1831151349
$1,108.84
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $735 · 2020: $374.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $185.37 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $121.73 | 2019 | |
| Janssen Pharmaceuticals, INC | $101.10 | 2019-2020 | |
| Novo Nordisk INC | $97.74 | 2019-2020 | |
| Glaxosmithkline, LLC. | $83.88 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $81.79 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $76.82 | 2019-2020 | |
| Allergan, INC. | $56.15 | 2019-2020 | |
| Astellas Pharma US INC | $51.01 | 2019-2020 | |
| Sanofi Pasteur INC. | $39.71 | 2019-2020 | |
| Amarin Pharma, INC. | $36.99 | 2019-2020 | |
| Radius Health, INC. | $30.79 | 2019-2020 | |
| Scilex Pharmaceuticals INC. | $27.78 | 2019 | |
| Lilly USA, LLC | $25.65 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $25.47 | 2019 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $25.13 | 2019 | |
| Therapeuticsmd, INC. | $24.64 | 2019 | |
| Abbott Laboratories | $17.09 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carol Wolfe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.